XML 22 R6.htm IDEA: XBRL DOCUMENT v3.25.4
Consolidated Statements of Changes in Stockholders’ Equity (Capital Deficiency) - USD ($)
$ in Thousands
Preferred Shares
Redeemable Convertible
Common Stock
Additional paid in capital
Accumulated deficit
Total
Balance at Dec. 31, 2023 $ 3 $ 166,048 $ (162,970) $ 3,081
Balance (in Shares) at Dec. 31, 2023 314,943 [1]      
Issuance of Common Stock, Merger Warrants and Redeemable Convertible Preferred Shares upon the APT acquisition, net of issuance cost [2] $ 12,561 $ 1 3,227 15,789
Issuance of Common Stock, Merger Warrants and Redeemable Convertible Preferred Shares upon the APT acquisition, net of issuance cost (in Shares) [2] 40,470 48,237 [1]      
Exercise of Pre-Funded Warrants into shares of Common Stock $ 1 5 6
Exercise of Pre-Funded Warrants into shares of Common Stock (in Shares) [1]   76,770      
Issuance of Common Stock under the At the Market Sales Agreement, net of issuance costs [2] [3] 19 [3] 19
Issuance of Common Stock under the At the Market Sales Agreement, net of issuance costs (in Shares) [2] 396 [1]      
Issuance of Redeemable Convertible Preferred Shares upon March 2024 PIPE, net of issuance costs [2] $ 19,859 541 20,400
Issuance of Redeemable Convertible Preferred Shares upon March 2024 PIPE, net of issuance costs (in Shares) [2] 216,417 [1]      
Conversion of Redeemable Convertible Preferred Shares into Common Stock $ (13,775) $ 1 13,774
Conversion of Redeemable Convertible Preferred Shares into Common Stock (in Shares) (109,152) 574,484 [1]      
Issuance of Common Stock upon restricted stock units (“RSUs”) vesting [3] [3]
Issuance of Common Stock upon restricted stock units (“RSUs”) vesting (in Shares) [1]   8,180      
Stock-based compensation expenses     2,580   2,580
Net loss       (17,727) (17,727)
Balance at Dec. 31, 2024 $ 18,645 $ 6 186,194 (180,697) 24,148
Balance (in Shares) at Dec. 31, 2024 147,735 1,023,010 [1]      
Issuance of Common Stock, Registered Pre-Funded Warrants and Private Pre-Funded Warrants under the February 2025 SPA, net of issuance costs [2] [3] 878 [3] 878
Issuance of Common Stock, Registered Pre-Funded Warrants and Private Pre-Funded Warrants under the February 2025 SPA, net of issuance costs (in Shares) [2] 148,857 [1]      
Issuance of Common Stock under the Inducement Letter Agreements [2] $ 1 6,472 6,473
Issuance of Common Stock under the Inducement Letter Agreements (in Shares) [2] 208,479 [1]      
Exercise of Private Pre-Funded Warrants and Common Warrants [2] [3] 2 2
Exercise of Private Pre-Funded Warrants and Common Warrants (in Shares) [2] 75,223 [1]      
Exercise of options to Common Stock [4] [3] [3] [3] [3]
Exercise of options to Common Stock (in Shares) [4] 718 [1]      
Vested restricted stock units [4] [3] [3] [3]
Vested restricted stock units (in Shares) [4] 14,469 [1]      
Issuance of Common Stock under the At the Market Sales Agreement, net of issuance costs [2] [3] 1,305 [3] 1,305
Issuance of Common Stock under the At the Market Sales Agreement, net of issuance costs (in Shares) [2] 121,773 [1]      
Conversion of Redeemable Convertible Preferred Shares into Common Stock [2] $ (28) [3] 28 [3]
Conversion of Redeemable Convertible Preferred Shares into Common Stock (in Shares) [2] (223) 1,174 [1]      
Stock-based compensation expenses     2,091   2,091
Net loss       (36,199) (36,199)
Balance at Dec. 31, 2025 $ 18,617 $ 7 $ 196,970 $ (216,896) $ (1,302)
Balance (in Shares) at Dec. 31, 2025 147,512 1,593,703 [1]      
[1] All share amounts have been retroactively adjusted to reflect a 1-for-19 reverse share split as discussed in Note 12A.
[2] See note 12A.
[3] Less than $1.
[4] See note 12B.